Why hasn't eliminating acute rejection improved graft survival?

Jogi Raju Tantravahi, Karl L. Womer, Bruce Kaplan

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Although patients with end-stage renal disease can be maintained with dialysis therapy, the superiority of patient survival with renal transplantation makes transplantation the preferred method of renal replacement. Potent immunosuppressive therapies, particularly calcineurin inhibitors, have greatly reduced the incidence of acute rejection. However, long-term allograft survival remains limited. We discuss the impact of acute rejection on long-term allograft survival and discuss other factors leading to late allograft loss, including calcineurin inhibitor toxicity, chronic allograft nephropathy, and BK virus nephropathy, as well as donor and recipient factors associated with long-term allograft loss.

Original languageEnglish (US)
Title of host publicationAnnual Review of Medicine
Editors Caskey, Austin, Hoxie
Pages369-385
Number of pages17
DOIs
StatePublished - May 11 2007

Publication series

NameAnnual Review of Medicine
Volume58
ISSN (Print)0066-4219

Keywords

  • Allograft survival
  • BK virus nephropathy
  • Calcineurin inhibitor toxicity
  • Chronic allograft nephropathy
  • Donor and recipient factors
  • Kidney transplantation

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Why hasn't eliminating acute rejection improved graft survival?'. Together they form a unique fingerprint.

  • Cite this

    Tantravahi, J. R., Womer, K. L., & Kaplan, B. (2007). Why hasn't eliminating acute rejection improved graft survival? In Caskey, Austin, & Hoxie (Eds.), Annual Review of Medicine (pp. 369-385). (Annual Review of Medicine; Vol. 58). https://doi.org/10.1146/annurev.med.58.061705.145143